Method of production of inhalable composite particles using a three-fluid nozzle

Abstract

A method of preparing a pharmaceutical formulation which is suitable for inhalation, the method comprising: providing a solution comprising a first solvent or mixture of solvents and a poorly water soluble active agent; providing a second solution comprising a second solvent or mixture of solvents and an excipient. The first and second solvents or mixture of solvents are removed by simultaneously drying both solutions in a spray dryer equipped with a three-fluid nozzle to produce particles comprising an active agent and an excipient.

Claims

1. A method of preparing a dry powder inhalation pharmaceutical formulation, the method comprising: providing a first solution comprising a first solvent and an Active Pharmaceutical Agent (API), wherein the API is an active agent which requires at least 30 grams of water to dissolve one gram of solid at a temperature of 20° C.; providing a second solution comprising a second solvent and at least one excipient; and removing the first and second solvents by simultaneously drying both the first and second solutions in a spray dryer having an external mixing three-fluid nozzle that produces one or more particles comprising both the API and the at least one excipient; wherein the first solvent is a different solvent to the second solvent, wherein the first solvent is an organic solvent or a mixture containing at least an organic solvent and water and wherein the second solvent is water or a mixture containing at least water and an organic solvent, wherein the at least one excipient is more soluble in water than the API, wherein the API is more soluble in the organic solvent than the at least one excipient, and wherein the at least one excipient comprises one or more component selected from the group consisting of: amino acids; sugars; and mixtures thereof.

2. The method according to claim 1, wherein the one or more particles have a mass median diameter of less than 5 μm.

3. The method according to claim 1, wherein the one or more particles comprise the at least one excipient at least partially encapsulating the active agent.

4. The method according to claim 1, wherein the one or more particles comprise the at least one excipient totally encapsulating the active agent.

5. The method according to claim 1, wherein the at least one excipient is a stabilizing agent.

6. The method according to claim 1, wherein the sugars are selected from lactose, trehalose, or raffinose.

7. The method according to claim 1, wherein the amino acids are selected from leucine, iso-leucine, tri-leucine or isomers thereof.

8. The method according to claim 1, wherein the at least one excipient comprises trehalose and leucine.

9. The method according to claim 1, wherein the external mixing three-fluid nozzle comprises an inner channel and an outer channel, and wherein the first solution is fed to the inner channel and the second solution is fed to the outer channel.

10. The method according to claim 1, wherein the feed rate of the second solution is always higher than the feed rate of the first solution.

11. A pharmaceutical composition obtained by the method according to claim 1.

12. The method according to claim 2, wherein the sugars are selected from lactose, trehalose, or raffinose.

13. The method according to claim 2, wherein the amino acids are selected from leucine, iso-leucine, tri-leucine or isomers thereof.

14. The method according to claim 2, wherein the at least one excipient comprises trehalose and leucine.

15. The method according to claim 9, wherein the sugars are selected from lactose, trehalose, or raffinose.

16. The method according to claim 9, wherein the amino acids are selected from leucine, iso-leucine, tri-leucine or isomers thereof.

17. The method according to claim 9, wherein the at least one excipient comprises trehalose and leucine.

18. The method according to claim 15, wherein the feed rate of the second solution is always higher than the feed rate of the first solution.

19. The method according to claim 16, wherein the feed rate of the second solution is always higher than the feed rate of the first solution.

20. The method according to claim 17, wherein the feed rate of the second solution is always higher than the feed rate of the first solution.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The present invention will now be described solely by way of example and with reference to the accompanying drawings in which:

(2) FIG. 1: SEM micrographs of the dry particles produced using the three-fluid nozzle under the different production conditions: Trial #1 to #5.

(3) FIG. 2: Scheme of a conventional laboratory scale spray dryer, equipped with a two-fluid nozzle.

(4) FIG. 3: Scheme of a laboratory scale spray dryer applied in the example, equipped with a three-fluid nozzle.

(5) FIG. 4: Bottom view of the three-fluid nozzle internal distribution piping.

DETAILED DESCRIPTION OF THE INVENTION

(6) a) The invention makes use of a spray dryer apparatus equipped with a three-fluid nozzle as means to form particles from two independent solutions, as depicted in FIG. 3 and FIG. 4, which enables the production of composite particles for inhalation purposes with a good aerodynamic performance and without the solubility limitations observed when a single solution is prepared and the components present different solubility requirements.

(7) b) As shown in FIG. 2, there is shown prior-art spray drying apparatus generally indicated (10) comprising an external two-fluid nozzle, generally indicated (20), which feeds into a drying chamber, generally indicated (30). Feeding into the external two-fluid nozzle (20) is an atomizing gas feed, generally indicated (22), and a liquid feed generally indicated (24). The nozzle (20) comprises two concentric flow paths. The first, outermost flow path comprises a first inlet linked to a first outlet. The second, innermost flow path comprises a second inlet linked to a second outlet. The atomizing gas feed (22) is linked to the first inlet, and the first fluid feed (24) is linked to the second inlet.

(8) c) The drying chamber (30) is linked to a source of drying gas. Drying gas is circulated through the drying chamber (30) via a fan (34) via a heat exchanger (36), a condenser (38) and a cyclone (90).

(9) d) The present invention is described in FIGS. 3 and 4. Some apparatus is equivalent to that of the prior art apparatus shown in FIG. 2, and in those instances like reference numerals are used. FIGS. 3 and 4 show spray drying apparatus according to the present invention generally indicated (100) comprising an external three-fluid nozzle, generally indicated (120), which feeds into a drying chamber, generally indicated (30). Feeding into the external three-fluid nozzle (120) is an atomizing gas feed, generally indicated (122), and a first liquid feed generally indicated (140) and a second liquid feed, generally indicated (150). The nozzle (120), as shown in FIGS. 3 and 4, comprises three concentric flow paths, generally indicated (160), (170) and (180). The first, outermost flow path comprises a first inlet (162) linked to a first outlet (164). The second, innermost flow path (170) comprises a second inlet (172) linked to a second outlet (174), and the third, middle flow path (180) comprises a third inlet (182) linked to a third outlet (184). The atomizing gas feed (122) is linked to the first inlet (162), the first fluid feed (140) is linked to the second inlet (172) and the second fluid feed (150) is linked to the third inlet (182).

(10) e) The drying chamber (30) is linked to a source of drying gas. Drying gas is circulated through the drying chamber (30) via a fan (34) via a heat exchanger (36), a condenser (not shown) and a cyclone (90).

(11) f) In the spray-drying process, the two different liquid feed streams (140 and 150) are concentrically delivered to the drying chamber (30) and are atomized into droplets due to the atomizing gas feed (122). When these droplets enter the drying chamber (30), along with co-current drying gas, the droplets undergo an evaporation process in which the solvent(s) are removed, forming a dry powder that is afterwards carried by the gas and collected in the cyclone (90) (or other collecting system such as a filter bag or a electrostatic precipitator).

(12) g) By using the three-fluid nozzle approach, there are no component solubility limitations, since two separate solutions are prepared and concentrically delivered to the nozzle (120), which allows more flexibility on the spray drying parameters and formulation composition choice and potentially higher solids throughput.

(13) h) The inner feed (140) can comprise the API dissolved in a solvent or mixture of solvents at a given concentration of solids (C_solids_in) while the outer feed (150) can comprise the excipient(s) dissolved at a given concentration of solids (C_solids_out) in a solvent or solvents mixture.

(14) i) Each channel can deliver a solution or suspension, but preferably a solution.

(15) j) An appropriate aerodynamic performance of the inhalable composite particles is determined by the combination of the optimal formulation composition and the spray drying process parameters, namely solvent composition, first liquid feed (140), second liquid feed (150), C_solids_in, C_solids_out, T_out and atomization gas flow (122), amongst others.

(16) k) The current invention is particularly advantageous for preparing pharmaceutical compositions of poorly water soluble APIs. Herein, poorly water soluble APIs are defined as any active substance that will require at least 30 parts of water to dissolve one gram of solid at a temperature of 20° C.

(17) The main advantages of the present invention include: No solubility limitations for the API(s)/excipient(s) since two independent solutions/suspensions are prepared; Higher process flexibility since an individual control of each feed flow rate (140, 150) and composition can be performed; Higher process throughput since there are no solubility limitations for the API while maintaining a good aerodynamic performance. Better control over the coating/encapsulation degree of the API; Lower final residual organic solvent content since the solvent quantities required to dissolve the API would be lower when compared with the standard two-fluid nozzle; Simpler process when comparing with other conventional encapsulating methodologies.

(18) As used herein, “API” includes any physiologically or pharmacologically active substance that produces a localized or systemic effect in a patient. The active agent can comprise but is not limited to, for example, antibiotics, antifungal agents, antiviral agents, anepileptics, analgesics, anti-inflammatory agents, bronchodilators, and viruses and may be inorganic and organic compounds, including, without limitation, drugs which act on the peripheral nerves, adrenergic receptors, cholinergic receptors, the skeletal muscles, the cardiovascular system, smooth muscles, the blood circulatory system, synaptic sites, neuroeffector junctional sites, endocrine and hormone systems, the immunological system, the reproductive system, the skeletal system, autacoid systems, the alimentary and excretory systems, the histamine system and the central nervous system. Suitable agents may be selected from, for example, polysaccharides, steroids, hypnotics and sedatives, psychic energizers, tranquilizers, anticonvulsants, muscle relaxants, antiparkinson agents, anti-inflammatories, muscle contractants, antimicrobials, antimalarials, hormonal agents including contraceptives, sympathomimetics, polypeptides, and proteins capable of eliciting physiological effects, diuretics, lipid regulating agents, antiandrogenic agents, antiparasitics, neoplastics, antineoplastics, hypoglycemics, nutritional agents and supplements, growth supplements, fats, antienteritis agents, electrolytes, vaccines and diagnostic agents.

(19) The active agent of the present invention may be combined with pharmaceutical carriers or excipients. These excipients can be used as bulking agents or to improve coating and/or to improve the stability and/or dispersibility of the powder. The excipients can be delivered via pulmonary route, with or without the active agent, for example, in placebo trials. The excipients include but are not limited to carbohydrates, amino acids, salts, peptides and proteins, alditols, biodegradable polymers, surfactants, amongst others. The solvent/solvents system used can comprise but are not limited to water, organic acids, such as acetic acid, an alcohol, an amine, an aldehyde, a ketone, an ester, a halide, an aromatic, and/or an alkane.

EXAMPLE

(20) The aerodynamic performance and the drug uniformity results of the experiments described below demonstrate a successful proof-of-concept for the current invention and is not limiting of the same.

(21) In these experiments the conventional two-fluid nozzle (1 liquid and 1 gas channel)—as shown in FIG. 2—was substituted by a three-fluid nozzle (2 liquid and 1 gas channel) in the spray drying apparatus as shown in FIG. 3. The two fluids and gas are delivered concentrically as shown in FIG. 3 and FIG. 4. Two separate solutions were prepared. Solution 1 was prepared by dissolving the API, fluticasone propionate (FP), in an ethanol system, while solution 2 was prepared by dissolving trehalose and L-leucine (80:20 w/w) in a water/ethanol system (50:50 v/v), to be delivered through the inner and outer liquid channels, respectively.

(22) A laboratory scale spray dryer (BUCHI model B-290 Advanced) was used to process the above feed solutions (solution 1 and solution 2). In all trials, the BUCHI unit was equipped with a single external three-fluid nozzle with an inner feed orifice diameter of 0.7 mm, outer feed orifice diameter of 2.0 mm and cap with 2.8 mm of diameter. The F_drying gas and F_feed of the first solution (140) was kept constant at 35 kg/h and 1 mL/min, respectively.

(23) In Trials #1, #2, #3, several process/formulation parameters were kept constant—Table 1. The composition of solution 1 and solution 2 remained unaltered, as well as the rotameter and the feed flow of the first fluid solution (solution 1) (140) and the feed flow of the second fluid feed solution (solution 2) (150). The spray drying conditions used in trial #1 are presented in Table 1. In trial #2, the effect of decreasing the outlet temperature of the drying gas (T_out) was evaluated, T_out ˜65° C. In trial #3, the impact of decreasing the amount of atomization gas was assessed by decreasing the atomization gas flow from 60 to 45 mm in the rotameter, while maintaining the T_out at 95° C.

(24) In trial #4, the API percentage relative to the total solids was of 5% w/w. To evaluate the API powder uniformity, 5 samples of 100±0.1 mg were weighted and dissolved in a 100 mL volumetric flask. The API content uniformity was assessed and it was observed that the API uniformity is ensured, obtaining a relative standard deviation (RSD) of 1.27%. According to these RSD results, it may be assumed that all trials that contain 1% of the total solids of FP API are uniformly dispersed in the particles formed.

(25) In trial #5, the second fluid feed (150) was increased from 4 to 10 mL/min to assess the impact on the powder aerodynamic performance.

(26) To assess the powder aerodynamic performance, a Fast Screening Impactor (FSI) was used to determine fine particle fraction (FPF) of the generated composite particles. Hypromellose (HPMC) size 3 capsules were hand filled with 20 mg of powder and were actuated using a Plastiape RH model 7 at 60 L/min, 4 kPa. The tests were performed in duplicate.

(27) Trials #1, #2 and #4 returned FPF values, relative to the powder emitted dose (FPFED), from 76 up to 86%, showing an aerodynamic performance suitable for pulmonary delivery. The preparation of two individual solutions enabled the production of composite particles without any solubility limitations from the API and excipients point-of-view, while maintaining a good process yield. If a single solution was prepared, a careful balance between the solvents ratio and the API/excipients concentration would be required with clear composition limitations.

(28) Based on the FPFED values of trials #2 and #5, it can be concluded that lower atomization and higher second fluid feed values tend to promote lower aerodynamic performance.

(29) The SEM images of the powders produced are presented in FIG. 1. Based on the SEM micrographs of all 5 trials, it is possible to observe that all particles are within the inhalable range (particle size below 5 μm) and that in all cases, fragmented particles or particles with an opening at the surface are observed.

(30) TABLE-US-00001 Trial #1 #2 #3 #4 #5 First fluid solution mL/min 1 1 1 1 1 C_solids_in % w/v 0.08 0.08 0.08 0.4 0.18 (ethanol) Second fluid mL/min 4 4 4 4 9 solution C_solids_out % w/v 2 2 2 1.9 0.4 (water/ethanol) (50:50) Rotameter mm 60 60 45 60 60 T_out ° C. 95 65 95 65 65 Powder Properties FPF.sub.ED (FSI; n = 2) % 79.1 86.3 50.6 76.2 73.7 Process yield % 72.1 82.4 83.1 72.3 70.1 Note: F_drying—drying gas flow rate; first fluid solution—solution flow rate from the inner channel; second fluid solution—solution flow rate from the outer channel; C_solids_in—concentration of solids in the inner channel solution; C_solids_out—concentration of solids in the outer channel solution; T_out—outlet temperature of the drying gas; FPF.sub.ED—fine particle fraction relative to the emitted dose from the capsule.

(31) These results support the concept that, by using a three-fluid nozzle, particles with a high FPF and a uniform API content can be obtained. In all cases, a higher or smaller number of fragmented particles were observed. The production method of these particles is not limited by the API(s)/excipient(s) solubility. Hence, the results herein presented demonstrate the success of the current proof-of-concept and, in this way, the feasibility of using a three-fluid nozzle for the production of composite particles, capable of fulfilling all the previous aims and goals.

REFERENCES

(32) [1] S. Palakodaty and P. York, “Phase behavioral effects on particle formation processes using supercritical fluids,” Pharm. Res., vol. 16, no. 7, pp. 976-985, 1999. [2]K. Kondo, T. Niwa, and K. Danjo, “Preparation of sustained-release coated particles by novel microencapsulation method using three-fluid nozzle spray drying technique,” Eur. J. Pharm. Sci., vol. 51, pp. 11-19, 2014. [3]F. Wan, M. J. Maltesen, S. K. Andersen, S. Bjerregaard, C. Foged, J. Rantanen, and M. Yang, “One-Step Production of Protein-Loaded PLGA Microparticles via Spray Drying Using 3-Fluid Nozzle.,” Pharm. Res., no. 10, February 2014. [4]J. Legako and N. T. Dunford, “Effect of spray nozzle design on fish oil-whey protein microcapsule properties,” J. Food Sci., vol. 75, no. 6, 2010. [5]R. M. Pabari, T. Sunderland, and Z. Ramtoola, “Investigation of a novel 3-fluid nozzle spray drying technology for the engineering of multifunctional layered microparticles,” Expert Opin. Drug Deliv., pp. 1-12, 2012.